Adam Mayers

Jul 23, 2024 | buildingwealth.ca | Adam Mayers

By Adam Mayers, Contributing EditorShareholders in Walt Disney Co. (NYSE: DIS) had reason to feel better this year as a reorganization and restructuring plan seemed to point to brighter days ahead. There is no question things have improved. Pandemic shocks are over, theme parks and cruise lines are booming, and strategic investments look promising. The Disney+ streaming service, though expensive, has turned a corner, and offers growth at a time when traditional TV viewing is eroding.

Sep 13, 2023 | theglobeandmail.com | Adam Mayers

Sign up for the Globe Advisor weekly newsletter for professional financial advisors on our sign-up page. Get exclusive investment industry news and insights, the week’s top headlines, and what you and your clients need to know. For more from Globe Advisor, visit our homepage. A year ago, the price of electric vehicles (EVs) was rising as manufacturers struggled to find enough parts to meet growing demand. This year, there are plenty of parts, but even so, unsold cars are piling up in dealer lots.

Aug 31, 2023 | jacobin.com | Adam Mayers

Australia’s public sector union, the Community and Public Sector Union (CPSU) PSU Group is in a vexed position. It has spent the last decade watching its membership decline severely while earnestly campaigning for an Australian Labor Party (ALP) government in the hope that it will bargain in good faith. Now the limits of this strategy are playing out. Labor is in office, and bargaining over pay and conditions in the public service is in full swing — and the government is not delivering.

Aug 24, 2023 | theglobeandmail.com | Adam Mayers

Sign up for the Globe Advisor weekly newsletter for professional financial advisors on our sign-up page. Get exclusive investment industry news and insights, the week’s top headlines, and what you and your clients need to know. For more from Globe Advisor, visit our homepage. Elective surgeries got back on track last year after several years of stop-and-start delays, but a series of headwinds put a dent in the sector’s rebound.

Aug 2, 2023 | theglobeandmail.com | Adam Mayers

Sign up for the Globe Advisor weekly newsletter for professional financial advisors on our sign-up page. Get exclusive investment industry news and insights, the week’s top headlines, and what you and your clients need to know. For more from Globe Advisor, visit our homepage. Breakthroughs in the effectiveness of a class of medicines designed to treat diabetes have become the most talked about drug developments in recent memory, mainly because of their extraordinary impact on obesity.